Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Kelly Financial Services LLC

Kelly Financial Services LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,108 shares of the company’s stock after selling 94 shares during the quarter. Kelly Financial Services LLC’s holdings in Johnson & Johnson were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Itau Unibanco Holding S.A. boosted its position in Johnson & Johnson by 7.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 3,018 shares of the company’s stock valued at $441,000 after purchasing an additional 211 shares during the period. Harmony Asset Management LLC boosted its position in Johnson & Johnson by 22.2% during the 2nd quarter. Harmony Asset Management LLC now owns 19,211 shares of the company’s stock valued at $2,808,000 after purchasing an additional 3,490 shares during the period. Magnetar Financial LLC acquired a new position in Johnson & Johnson during the 2nd quarter valued at approximately $80,751,000. Evergreen Capital Management LLC boosted its position in Johnson & Johnson by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 110,063 shares of the company’s stock valued at $16,087,000 after purchasing an additional 4,009 shares during the period. Finally, Providence Capital Advisors LLC boosted its position in Johnson & Johnson by 12.4% during the 2nd quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company’s stock valued at $5,979,000 after purchasing an additional 4,500 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.5 %

Shares of Johnson & Johnson stock opened at $147.03 on Tuesday. The stock’s fifty day moving average is $148.51 and its 200-day moving average is $156.10. The firm has a market capitalization of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on JNJ shares. Morgan Stanley boosted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Finally, Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.29.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.